Dr. Puhlmann has worked in oncology drug development for 20 years, and worked as the franchise head of global clinic development at Seagen. He also held positions with Merck & Co, Schering Plough, Bayer and Amgen and the National Cancer Institute.
“The opportunity to lead the development of Viewpoint’s pipeline programs is extremely exciting for me as a cancer drug developer. I think the application of targeted alpha-particle therapy will have a profound impact on the treatment of oncology patients,” Dr. Puhlmann said in an Oct. 4 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.